{"id":566,"date":"2022-01-28T12:04:00","date_gmt":"2022-01-28T17:04:00","guid":{"rendered":"https:\/\/www.napra.ca\/?p=566"},"modified":"2022-08-17T12:05:51","modified_gmt":"2022-08-17T16:05:51","slug":"recommandations-definitives-quant-a-la-solution-ophtalmique-de-tartrate-de-brimonidine-a-une-concentration-inferieure-ou-egale-a-0025-%ef%bf%bc","status":"publish","type":"post","link":"https:\/\/www.napra.ca\/fr\/recommandations-definitives-quant-a-la-solution-ophtalmique-de-tartrate-de-brimonidine-a-une-concentration-inferieure-ou-egale-a-0025-%ef%bf%bc\/","title":{"rendered":"Recommandations d\u00e9finitives quant \u00e0 la solution ophtalmique de tartrate de brimonidine \u00e0 une concentration inf\u00e9rieure ou \u00e9gale \u00e0 0,025 %\u00a0\ufffc"},"content":{"rendered":"\n<p>Le 6 d\u00e9cembre 2021, le Comit\u00e9 consultatif national sur les annexes de m\u00e9dicaments (CCNAM) a propos\u00e9 les recommandations provisoires suivantes (disponibles qu&rsquo;en anglais) :<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Brimonidine tartrate ophthalmic solution in concentrations up to and including 0.025%, used for the relief of redness of the eye due to minor eye irritations caused by environmental allergies, dryness and fatigue for adults of 18 years and older be granted Schedule III status, subject to the removal from the Prescription Drug List (PDL)<\/li><li>Brimonidine or its salts,&nbsp;<strong>except<\/strong>&nbsp;when sold as brimonidine tartrate ophthalmic solution in concentrations up to and including 0.025%, used for the relief of redness of the eye due to minor eye irritations caused by environmental allergies, dryness and fatigue for adults of 18 years and older will remain in Schedule I (as per the Prescription Drug List)<\/li><\/ul>\n\n\n\n<p>Ces recommandations ont \u00e9t\u00e9 finalis\u00e9es le 25 janvier 2022. Le conseil d\u2019administration de l\u2019ANORP a approuv\u00e9 les recommandations provisoires en tenant compte des commentaires re\u00e7us au cours de la p\u00e9riode d\u2019examen de trente jours. Les Annexes nationales de m\u00e9dicaments seront r\u00e9vis\u00e9es en cons\u00e9quence lorsque la substance concern\u00e9e sera retir\u00e9e de la Liste des drogues sur ordonnance.&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Le 6 d\u00e9cembre 2021, le Comit\u00e9 consultatif national sur les annexes de m\u00e9dicaments (CCNAM) a propos\u00e9 les recommandations provisoires suivantes (disponibles qu&rsquo;en anglais) : Brimonidine tartrate ophthalmic solution in concentrations [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":443,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[18],"tags":[],"class_list":["post-566","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-mises-a-jour-des-anm"],"acf":[],"uagb_featured_image_src":{"full":["https:\/\/www.napra.ca\/wp-content\/uploads\/2022\/08\/news-NDS-generic.png",660,440,false],"thumbnail":["https:\/\/www.napra.ca\/wp-content\/uploads\/2022\/08\/news-NDS-generic-150x150.png",150,150,true],"medium":["https:\/\/www.napra.ca\/wp-content\/uploads\/2022\/08\/news-NDS-generic-300x200.png",300,200,true],"medium_large":["https:\/\/www.napra.ca\/wp-content\/uploads\/2022\/08\/news-NDS-generic.png",660,440,false],"large":["https:\/\/www.napra.ca\/wp-content\/uploads\/2022\/08\/news-NDS-generic.png",660,440,false],"1536x1536":["https:\/\/www.napra.ca\/wp-content\/uploads\/2022\/08\/news-NDS-generic.png",660,440,false],"2048x2048":["https:\/\/www.napra.ca\/wp-content\/uploads\/2022\/08\/news-NDS-generic.png",660,440,false],"gform-image-choice-sm":["https:\/\/www.napra.ca\/wp-content\/uploads\/2022\/08\/news-NDS-generic.png",300,200,false],"gform-image-choice-md":["https:\/\/www.napra.ca\/wp-content\/uploads\/2022\/08\/news-NDS-generic.png",400,267,false],"gform-image-choice-lg":["https:\/\/www.napra.ca\/wp-content\/uploads\/2022\/08\/news-NDS-generic.png",600,400,false]},"uagb_author_info":{"display_name":"Stephanie Smith","author_link":"https:\/\/www.napra.ca\/fr\/author\/stephflow\/"},"uagb_comment_info":0,"uagb_excerpt":"Le 6 d\u00e9cembre 2021, le Comit\u00e9 consultatif national sur les annexes de m\u00e9dicaments (CCNAM) a propos\u00e9 les recommandations provisoires suivantes (disponibles qu&rsquo;en anglais) : Brimonidine tartrate ophthalmic solution in concentrations [&hellip;]","_links":{"self":[{"href":"https:\/\/www.napra.ca\/fr\/wp-json\/wp\/v2\/posts\/566","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.napra.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.napra.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.napra.ca\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.napra.ca\/fr\/wp-json\/wp\/v2\/comments?post=566"}],"version-history":[{"count":0,"href":"https:\/\/www.napra.ca\/fr\/wp-json\/wp\/v2\/posts\/566\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.napra.ca\/fr\/wp-json\/wp\/v2\/media\/443"}],"wp:attachment":[{"href":"https:\/\/www.napra.ca\/fr\/wp-json\/wp\/v2\/media?parent=566"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.napra.ca\/fr\/wp-json\/wp\/v2\/categories?post=566"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.napra.ca\/fr\/wp-json\/wp\/v2\/tags?post=566"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}